GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipella Pharmaceuticals Inc (NAS:LIPO) » Definitions » EBITDA Margin %

Lipella Pharmaceuticals (Lipella Pharmaceuticals) EBITDA Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Lipella Pharmaceuticals EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Lipella Pharmaceuticals's EBITDA for the three months ended in Mar. 2024 was $-1.19 Mil. Lipella Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Lipella Pharmaceuticals's EBITDA margin for the quarter that ended in Mar. 2024 was 0.00%.


Lipella Pharmaceuticals EBITDA Margin % Historical Data

The historical data trend for Lipella Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipella Pharmaceuticals EBITDA Margin % Chart

Lipella Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
-5.61 -717.76 -1,406.52 -1,023.56

Lipella Pharmaceuticals Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -152.89 -

Competitive Comparison of Lipella Pharmaceuticals's EBITDA Margin %

For the Biotechnology subindustry, Lipella Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lipella Pharmaceuticals's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipella Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Lipella Pharmaceuticals's EBITDA Margin % falls into.



Lipella Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Lipella Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-4.606/0.45
=-1,023.56 %

Lipella Pharmaceuticals's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-1.192/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lipella Pharmaceuticals  (NAS:LIPO) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Lipella Pharmaceuticals EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Lipella Pharmaceuticals's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipella Pharmaceuticals (Lipella Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
7800 Susquehanna Street, Suite 505, Pittsburgh, PA, USA, 15208
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's lead product candidates include LP-10 and LP-310.
Executives
Lori Birder director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Daniel R Cohen director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
David S. Battleman director C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
Byong Kim director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Jonathan H Kaufman director, 10 percent owner, officer: See Remarks C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Ryan Pruchnic director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Douglas Johnston officer: Chief Financial Officer C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Michael B Chancellor director, 10 percent owner, officer: Chief Medical Officer C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Naoki Yoshimura director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208